Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 3/2013

01-09-2013 | Metabolic Complications and Comorbidity (JM Kilby, Section Editor)

Update on HIV/HCV Coinfection

Authors: Vincent Soriano, Eugenia Vispo, Jose Vicente Fernandez-Montero, Pablo Labarga, Pablo Barreiro

Published in: Current HIV/AIDS Reports | Issue 3/2013

Login to get access

Abstract

Liver disease is currently one of the leading causes of hospitalization and death in HIV-positive individuals. Coinfection with the hepatitis C virus (HCV) is a major contributor to this trend. Besides hepatic damage, which is enhanced in the presence of HIV-associated immunosuppression, HCV may contribute to disease in coinfected individuals by potentiating immune activation and chronic inflammation, which ultimately account for an increased risk of cardiovascular events, kidney disease, and cancers in this population. Fortunately, hepatitis C therapeutics has entered a revolutionary era in which we hope that most patients treated with the new oral direct-acting antivirals (DAA) will be cured. However, many challenges preclude envisioning a prompt elimination of HCV from the coinfected population. Issues that should be addressed include the following: (1) rising incidence of acute hepatitis C in men who have sex with men, and expansion/recrudescence of injection drug use in some settings/regions; (2) adverse drug interactions between antiretrovirals and DAA; and (3) high cost of DAA, which may lead many to defer or fail to access appropriate therapy.
Literature
1.
Weber R, Sabin C, Friis-Moller N, et al. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med. 2006;166:1632–41.PubMedCrossRef
2.
Ruppik M, Ledergerber B, Rickenbach M, et al. Changing patterns of causes of death: SHCS, 2005 to 2009. 18th CROI, Boston, MA. Feb 27-March 2, 2011. [Abstract 789].
3.
Puoti M, Moioli MC, Travi G, Rosootti R. The burden of liver disease in HIV-infected patients. Semin Liver Dis. 2012;32:103–13.PubMedCrossRef
4.
Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and HCV: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073–89.PubMedCrossRef
5.
Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012;61 Suppl 1:47–58.CrossRef
6.
Barreiro P, Vispo E, Labarga P, Soriano V. Management and treatment of chronic hepatitis C in HIV patients. Semin Liver Dis. 2012;32:138–46.PubMedCrossRef
7.
Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis. 2004;38:128–33.PubMedCrossRef
8.
Grint D, Peters L, Reekie J, et al. Stability of HCV RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Med. (in press).
9.
Rockstroh J, Peters L, Grint D, et al. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? J Hepatol. (In press).
10.
Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA. 2000;283:74–80.PubMedCrossRef
11.
Soriano V, Puoti M, García-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1–13.PubMedCrossRef
12.
• Jones M, Nuñez M. Liver toxicity of antiretroviral drugs. Semin Liver Dis. 2012;32:167–76. This review updates the most recent knowledge on the mechanisms of antiretroviral-associated liver injury and propose strategies for rapid recognition and proper management.PubMedCrossRef
13.
Vispo E, Mena A, Maida I, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother. 2010;65:543–7.PubMedCrossRef
14.
Rockstroh J, Teppler H, Zhao J, et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med. 2012;13:127–31.PubMedCrossRef
15.
Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P, Soriano V. Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-HCV coinfected patients. AIDS. 2013;27:1187–8.PubMedCrossRef
16.
Labarga P, Soriano V, Vispo E, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis. 2007;196:670–6.PubMedCrossRef
17.
Soriano V, Sherman K, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-HCV coinfected patients. AIDS. 2011;25:2197–208.PubMedCrossRef
18.
Perez-Cachafeiro S, del Amo J, Iribarren JA, et al. Decrease in serial prevalence of coinfection with HCV among HIV-infected patients in Spain, 1997–2006. Clin Infect Dis. 2009;48:1467–70.PubMedCrossRef
19.
Ward J. The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease. Top Antivir Med. 2013;21:15–9.PubMed
20.
21.
Javaraman S, Chalabi Z, Perel P, Guerriero C, Roberts I. The risk of transfusion-transmitted infections in Sub-Saharan Africa. Transfusion. 2010;50:433–42.CrossRef
22.
Van der Helm J, Prins M, del Amo J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS. 2011;25:1083–91.PubMedCrossRef
23.
24.
Witt M, Seaberg E, Darilay A, et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis from 1984 to 2011. Clin Infect Dis. (in press).
25.
• AIDS European Treatment Network (NEAT). Acute hepatitis C in HIV-infected individuals: recommendations from the NEAT. AIDS. 2011;25:399–409. This article records the major conclusions reached by a group of European experts regarding the diagnosis and treatment of acute hepatitis C in HIV-infected persons. It particularly provides comprehensive and updated information on acute hepatitis C outbreaks among HIV-positive MSM.
26.
Sanchez-Parra C, Plaza Z, Vispo E, et al. Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. Liver Int. (in press).
27.
Deterding K, Grüner N, Buggisch P, et al. Delayed vs immediate treatment for patients with acute hepatitis C: a randomized controlled noninferiority trial. Lancet Infect Dis. (in press).
28.
Webster D, Wojcikiewicz T, Keller M, et al. Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin. Int J STD AIDS. (In press).
29.
Marco A, Esteban JI, Solé C, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol. (In press).
30.
Lambers F, Prins M, Thomas X, et al. Alarming incidence of HCV re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV MSM. AIDS. 2011;25:F21–7.PubMedCrossRef
31.
Mehta S, Genberg B, Astemborki J, et al. Limited uptake of hepatitis C treatment among injecting drug users. J Community. 2008;33:126–33.
32.
Chung R, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin vs interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451–9.PubMedCrossRef
33.
Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–50.PubMedCrossRef
34.
Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. JAMA. 2004;292:2839–48.PubMedCrossRef
35.
Nuñez M, Miralles C, Berdún MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in the treatment of chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Human Retroviruses. 2007;23:972–82.CrossRef
36.
• Grebely J, Oser M, Taylor L, Dore G. Breaking down the barriers to HCV treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J Infect Dis. 2013;207 Suppl 1:19–25. This article records the opinion of several experts about the ways to improve access to hepatitis C therapy in HIV-positive individuals, with particular attention to intravenous drug users and other marginal populations.CrossRef
37.
Poveda E, Vispo E, Barreiro P, et al. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain. Antivir Ther. 2012;17:571–5.PubMedCrossRef
38.
Soriano V, Garcia-Samaniego J. Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons. HIV Clin Trials. 2002;3:351–3.PubMedCrossRef
39.
Sanchez-Conde M, Montes-Ramirez ML, Miralles P, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/HCV-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat. 2010;17:280–6.PubMedCrossRef
40.
Limketkai B, Mehta S, Sutcliffe C, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA. 2012;308:370–8.PubMedCrossRef
41.
Fernández-Montero JV, Barreiro P, Vispo E, Labarga P, Sánchez-Parra C, Soriano V. Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. AIDS. (in press).
42.
Soriano V, Labarga P, Ruiz-Sancho A, Garcia-Samaniego J, Barreiro P. Regression of liver fibrosis in hepatitis C virus/HIV-coinfected patients after treatment with pegylated interferon plus ribavirin. AIDS. 2006;20:2225–7.PubMedCrossRef
43.
Macias J, del Valle J, Rivero A, et al. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV coinfection treated with pegylated interferon plus ribavirin. J Antimicrob Chemother. 2010;65:2204–11.PubMedCrossRef
44.
Barreiro P, Labarga P, Martín-Carbonero L, et al. Sustained virological response following HCV therapy is associated with nonprogression of liver fibrosis in HCV/HIV-coinfected patients. Antivir Ther. 2006;11:869–77.PubMed
45.
Soriano V, Maida I, Núñez M, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir Ther. 2004;9:987–92.PubMed
46.
Berenguer J, Alvarez-Pellicer J, Martin P, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with HIV and hepatitis C virus. Hepatology. 2009;50:407–13.PubMedCrossRef
47.
Berenguer J, Alvarez-Pellicer J, Carrero A, et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with HIV and hepatitis C virus. J Hepatol. (In press).
48.
Labarga P, Fernandez-Montero JV, Barreiro P, et al. Changes in liver fibrosis in HIV/HCV coinfected patients following different outcomes with peginterferon plus ribavirin therapy. Clin Infect Dis. (In press).
49.
Naggie S, Sulkowski M. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology. 2012;142:1324–34.PubMedCrossRef
50.
Soriano V, Labarga P, Fernandez-Montero JV, et al. The changing face of hepatitis C in the new era of direct-acting antivirals. Antivir Res. 2013;97:36–40.PubMedCrossRef
51.
• Lee M, Yang H, Lu S, et al. Chronic HCV infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469–77. This study represents a pivotal contribution on the long-term consequences of hepatitis C. Besides liver-related complications, it demonstrated that the rate of kidney disease, cardiovascular events, and some cancers increases in HCV carriers. Thus, as long as new more potent and safer curative drugs became available, treatment should not be restricted to those with advanced liver disease.PubMedCrossRef
52.
Peters L, Grint D, Lundgren J, et al. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS. 2012;26:1917–26.PubMedCrossRef
53.
Bedimo R, Westfall A, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med. 2010;11:462–8.PubMed
54.
Soriano V, Labarga P, Vispo E, Fernández-Montero JV, Barreiro P. Treatment of hepatitis C in patients infected with HIV in the direct-acting antiviral era. Infect Dis Clin North Am. 2012;26:931–48.PubMedCrossRef
55.
Sulkowski M. Current management of hepatitis C virus infection in patients with HIV coinfection. J Infect Dis. 2013;207(Suppl):26–32.CrossRef
56.
Thompson M, Aberg J, Hoy J, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308:387–402.PubMedCrossRef
57.
58.
Soriano V, Perelson A, Zoulim F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses. J Antimicrob Chemother. 2008;62:1–4.PubMedCrossRef
59.
Rein D, Smith B, Wittenborn J, et al. The cost-effectiveness of birth-control screening for hepatitis C antibody in US primary care settings. Ann Intern Med. 2012;156:263–70.PubMedCrossRef
60.
•• U.S. Preventive Services Task Force (USPSTF). New HIV guidelines. (in press). The USPSTF has recently acted decisively to accelerate routine HIV testing of all adults, following the steps taken for HCV by the CDC calling for one time testing of all baby boomers (born from 1945-1965), who are five times more likely than other adults to have HCV. In both HIV and HCV infections, expanding access to a simple test, used just one time, will identify more unaware infected people and get them treated with effective therapies while also dramatically reducing virus spread.
61.
Saifu H, Asch S, Goetz M, Smith J, Graber C, Schaberg D, et al. Evaluation of HIV and hepatitis C telemedicine clinics. Am J Manag Care. 2012;18:207–12.PubMed
62.
Sulkowski M, Sherman K, Dieterich D, et al. Telaprevir in combination with peginterferon and ribavirin for chronic HCV genotype 1 infection in HIV-infected patients. Ann Intern Med. (in press).
63.
van Heeswijk R, Beumont M, Kauffman R, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther. (in press).
64.
Mallolas J, Pol S, Rivero A, et al. Boceprevir plus peginterferon/ribavirin for the treatment of HIV-HCV coinfected patients: end of treatment week 48 interim results. 47th EASL, Barcelona April 2012. [Abstract 366].
65.
Hulskotte E, Feng H, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. 2013;56:718–26.PubMedCrossRef
66.
de Kanter C, Blonk M, Colbers A, Schouwenberg B, Burger D. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis. 2013;56:300–6.PubMedCrossRef
67.
Hammond K, Wolfe P, Burton J, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr. 2013;62:67–73.PubMedCrossRef
68.
Benito JM, Sanchez-Parra C, Barreiro P, et al. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. Antivir Ther. (in press).
69.
Cotte L, Braun J, Lascoux-Combe C, et al. High early virological response with telaprevir-pegylated interferon-ribavirin in treatment-experienced HCV genotype 1/HIV coinfected patients: ANRS HC26 TelapreVIH study. CROI 2013, Atlanta, GA, March 3–6 2013. [Abstract 36].
70.
Poizot-Martin I, Bellissant E, Piroth L, et al. ANRS HC27 BocepreVIH interim analysis: high early virologic response with boceprevir + pegylated interferón + ribavirin in HCV/HCV coinfected patients with previous failure to pegylated interferon + ribavirin. CROI 2013, Atlanta, GA, March 3–6, 2013. [Abstract 37].
71.
Medrano J, Neukam K, Rallon N, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis. 2010;51:1209–16.PubMedCrossRef
72.
Vispo E, Rallon N, Labarga P, Barreiro P, Benito JM, Soriano V. Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. J Clin Virol. 2012;55:58–61.PubMedCrossRef
73.
Rallon N, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin 28B gene with response to hepatitis C therapy in HIV/hepatitis C virus coinfected patients. AIDS. 2010;24:F23–9.PubMedCrossRef
74.
Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir with pegylated interferon/ribavirin in patients coinfected with chronic HCV and HIV-1: week 24 interim analysis of the TMC435-C212 study. CROI 2013, Atlanta, GA, March 3–6 2013. [Abstract 154LB].
75.
Zeuzem S, Soriano V, Asselah T, et al. Interferon-free treatment with faldaprevir and BI-207127 for genotype 1 HCV infection. N Engl J Med. (in press).
76.
Dieterich D, Soriano V, Nelson M, et al. STARTVerso 4: high rates of early virologic response in HCV genotype 1/HIV coinfected patients treated with faldaprevir + pegylated interferon and ribavirin. CROI 2013, Atlanta, GA, March 3–6, 2013. [Abstract 40LB].
77.
Sabo J, Kort J, Haschke M, et al. Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers. CROI 2013, Atlanta, GA. March 3–6, 2013, [Abstract 35].
78.
Soriano V, Vispo E, de Mendoza C, et al. Hepatitis C therapy with NS5B polymerase inhibitors. Exp Opin Pharmacother. (in press).
79.
Vispo E, Barreiro P, Soriano V. Pharmacokinetics of new oral hepatitis C antiviral drugs. Expert Opin Drug Metab Toxicol. 2013;9:5–16.PubMedCrossRef
80.
Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. (in press).
81.
Jacobson I, Gordon S, Kowdley K, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. (in press).
82.
Rodriguez-Torres M, Gonzales Rodriguez J, et al. HIV/HCV coinfected and HCV monoinfected patients have similar early HCV viral kinetics with the potent HCV nucleotide polymerase inhibitor sofosbuvir. ICAAC 2012, Sept 9–12 2012. [Abstract H–1921a].
83.
Golitsina N, Danehy F, Fellows R, Cretton-Scott E, Standring D. Evaluation of the role of three candidate human kinases in the conversion of the HCV inhibitor 2’-C-methyl-cytidine to its 5’-monophosphate metabolite. Antivir Res. 2010;85:470–81.PubMedCrossRef
84.
Guedi J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the HCV half-life. Proc Natl Acad Sci U S A. 2013;110:3991–6.CrossRef
85.
Lok A, Gardiner D, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216–24.PubMedCrossRef
86.
Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. (in press).
87.
Soriano V, Barreiro P, Sherman K. The changing epidemiology of liver disease in HIV patients. AIDS Rev. 2013;15:25–31.PubMed
88.
Maida I, Núñez M, Ríos MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr. 2006;42:177–82.PubMedCrossRef
89.
Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS. 2007;21:187–92.PubMedCrossRef
90.
Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case–control study. Clin Infect Dis. 2009;49:626–35.PubMedCrossRef
91.
Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Noncirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis. 2011;24:12–8.PubMedCrossRef
92.
Vispo E, Cevik M, Rockstroh J, et al. Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients. Clin Infect Dis. 2013;56:1117–22.PubMedCrossRef
93.
Vispo E, Maida I, Barreiro P, Moreno V, Soriano V. Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV-coinfected patients. HIV Clin Trials. 2008;9:440–4.PubMedCrossRef
94.
Sulkowski M, Gardiner D, Rodriguez-Torres M, et al. Sustained virological response with daclatasvir plus sofosbuvir +/− ribavirin in chronic HCV genotype 1 infected patients who previously failed telaprevir or boceprevir. J Hepatol. 2013;58(Suppl):570. [Abstract 1417].
95.
Ford N, Singh K, Cooke G, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis. 2012;54:1465–72.PubMedCrossRef
96.
Easterbrook P, Sands A, Harmanci H. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings. Sem Liver Dis. 2012;32:147–57.CrossRef
97.
Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML): a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. (in press).
Metadata
Title
Update on HIV/HCV Coinfection
Authors
Vincent Soriano
Eugenia Vispo
Jose Vicente Fernandez-Montero
Pablo Labarga
Pablo Barreiro
Publication date
01-09-2013
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 3/2013
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-013-0169-5

Other articles of this Issue 3/2013

Current HIV/AIDS Reports 3/2013 Go to the issue

Co-infections (MA Jacobson, Section Editor)

Impact of Community-Associated Methicillin Resistant Staphylococcus aureus on HIV-Infected Patients

Co-infections (MA Jacobson, Section Editor)

Clostridium Difficile Infection in Patients with HIV/AIDS

Metabolic Complications and Comorbidity (JM Kilby, Section Editor)

HIV and Neurocognitive Dysfunction

Metabolic Complications and Comorbidity (JM Kilby, Section Editor)

Solid Organ Transplants in HIV-Infected Patients

Co-infections (MA Jacobson, Section Editor)

Asymptomatic Cryptococcemia in Resource-Limited Settings

Co-infections (MA Jacobson, Section Editor)

Oral Health Considerations in HIV-Infected Children
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits